| MODULITH® SLC |
|
|
World's first shock wave device for cardiology
Innovation and experience
The MODULITH® SLC is the world’s first shock wave device for the treatment of refractory angina pectoris. Controlled application of precisely levelled shock wave pulses on ischemic areas of the heart muscle generates new capillaries (neo-angiogenesis) and increases circulation and metabolism. The effect is significant and lasting. Several thousand shock waves are delivered to the ischemic area under simultaneous inline-ultrasound control. ECG-triggering ensures shock wave release only during refractory period of the cardiac cycle, avoiding arrhythmic irritations. Significant reduction of complaints and enhanced cardiac function are achieved. The treatment modality does not require anaesthesia and is essentially free of side effects. VersatilityErgonomic The shock wave source of the MODULITH® SLC is mounted to a balanced articulated arm with hydraulic brakes. The device can be positioned and directed smoothly without effort. According to patients anatomy optimal positions and directions of shock wave access may be selected. Fine adjustment is controlled by a separate manual scanning mechanism. Minimal change of position and direction with the therapy head ensures optimal visualisation and control with ultrasound. Last but not least, individually matched shock waves are released and triggered by ECG to avoid risky interference with cardiac cycle of the patient. The whole device is built in a trolley to be easily moved into its operation position and stored when not in use.
Shock wave sourceShock wave source
|